CSL · 2 days ago
Director, AI & Advanced Analytics
CSL Behring is a global biotherapeutics leader focused on saving lives through innovative therapies. The Director of AI & Advanced Analytics will drive the implementation of AI/ML and advanced analytics solutions across R&D, ensuring alignment with business goals and facilitating user adoption through training and community building.
BiotechnologyHealth CareHealth DiagnosticsMedical
Responsibilities
Drives the implementation of AI/ML, advanced analytics, and automation solutions across R&D to improve scientific and operational outcomes
Supports strategy execution, capability development, and stakeholder engagement to deliver scalable, compliant innovation through digital agents and intelligent automation
Translate AI/ML and automation strategies into executable plans and projects across R&D functions
Lead development and operationalization of models, workflows, and agentic tools to support business goals
Champion governance practices for AI/ML and automation, including ethical use, validation, and MLOps
Collaborate with R&D business partners, IT, and external forums (e.g., Pistoia Alliance) to identify and prioritize impactful use cases
Facilitate user adoption through training, community building (e.g., guilds), and communication of success stories
Ensure alignment with enterprise data platforms and existing workflows for seamless integration
Monitor KPIs and support compliance documentation and audit readiness
Qualification
Required
Bachelor's or Master's in Data Science, Engineering, Computer Science, or related field
10+ years of experience in AI/ML, automation, or analytics in R&D or life sciences
Strong experience delivering production-ready models and workflow automation
Proficiency in data science platforms, ML Ops, scripting, and automation tools
Strong collaboration, vendor management, and technical leadership skills
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase